Jennifer L. Taubert - 10 Feb 2023 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, WW Chair, Pharmaceuticals
Signature
Raavi K. Deol, as attorney-in-fact for Jennifer L. Taubert
Issuer symbol
JNJ
Transactions as of
10 Feb 2023
Net transactions value
-$208,921
Form type
4
Filing time
14 Feb 2023, 15:36:18 UTC
Previous filing
04 Jan 2023
Next filing
15 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +3,570 +2.8% $0.000000 130,026 10 Feb 2023 Direct F1
transaction JNJ Common Stock Tax liability $208,921 -1,289 -0.99% $162.08 128,737 10 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Restricted Share Units Options Exercise $0 -3,570 -100% $0.000000* 0 10 Feb 2023 Common Stock 3,570 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Share Units awarded under Long-Term Incentive Plan on February 10, 2020 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting.
F2 Shares withheld for payment of taxes upon vesting of Restricted Share Units.